4.3 Review

Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies

Journal

JCO ONCOLOGY PRACTICE
Volume 19, Issue 5, Pages 278-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/OP.22.00710

Keywords

-

Categories

Ask authors/readers for more resources

Cisplatin is widely used in the treatment of various cancers, but it poses a risk of hearing impairment. Despite the lack of standardized guidelines for monitoring and treatment of cisplatin-induced ototoxicity, it remains a significant challenge in clinical practice. A review of literature and a survey of practicing oncologists reveal the need for standardization and effective prevention strategies.
Cisplatin is a bedrock of cancer management and one of the most used chemotherapeutic agents in the treatment of germ cell, lung, bladder, ovarian, and head and neck cancers. Approximately 500,000 patients diagnosed annually with these cancer types in the United States could be candidates for treatment with cisplatin. There is a 5-fold increase in the risk of hearing impairment or ototoxicity with cisplatin, which can manifest as ringing in the ear (tinnitus), high-frequency hearing loss, and at late stages, a decreased ability to hear normal conversation. More than half of adult and pediatric patients with cancer treated with cisplatin developed hearing impairment with major impact on patients' health-related quality of life. A considerable evidence gap persists regarding the burden and effective prevention and interception strategies for cisplatin-induced ototoxicity, especially in adult patients with cancer. We conducted a review of the published literature to provide an update on the status of this important clinical challenge. We also surveyed practicing oncologists within our network of academic and community practices to gain a better understanding of how the published literature compares with real-world practice. Our review of the literature showed a lack of standardized guidelines for monitoring and treatment of cisplatin-induced ototoxicity, especially in the adult cancer patient population. Our survey of practicing oncologists mirrored the findings from the published literature with a heterogeneity of practice, which highlights the need for standardization.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available